Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Sees Generics Production In India Way To Make Affordable Drugs (Japan)

This article was originally published in PharmAsia News

Executive Summary

An Eisai executive says the Japanese company is turning to India for expanded production of active pharmaceutical ingredients, in part because it cannot make drugs in Japan cheaply enough to make them affordable in poor countries. Takafumi Asano, an Esai vice president, also said the company expects to take advantage of production costs in India to make its own generics at a fraction of the price of its branded drugs. Asano added, during an interview along with Deputy President Soichi Matsuno, that the company would not be able to do so if it relied solely on its Kashima plant in Japan. The firm recently opened a second production plant for generics in India. (Click here for more - may require a subscription

You may also be interested in...



Device Week, 23. October 2020 – Conference Spotlight TCT, HLTH

In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting. 

Retrophin Bolsters Portfolio With Orphan Technologies Buyout

The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.

Dr Reddy's Isolates Data Service Centers Among Preventive Actions Responding To Cyberattack

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel